RVMD analyst estimates

Revolution Medicines (RVMD) analyst ratings, the average price target and its range, and every firm's latest call.

RVMD analyst ratings and price targets

DateFirmCallTarget
Oct 19, 2026Truist FinancialRevolution Medicines price target raised to $241 from $240 at Truist$241.00
Oct 14, 2026RBC CapitalRevolution Medicines price target raised to $260 from $259 at RBC Capital$260.00
Oct 8, 2026RBC CapitalRevolution Medicines price target raised to $259 from $251 at RBC Capital$259.00
Oct 7, 2026Truist FinancialRevolution Medicines price target raised to $240 from $239 at Truist$240.00
Sep 28, 2026Loop Capital MarketsBrookline Capital Markets Starts Revolution (RVMD) at Buy$318.00
Sep 24, 2026Goldman SachsRevolution Medicines resumed with a Buy at Goldman Sachs$267.00
Sep 10, 2026Morgan StanleyMorgan Stanley Starts Revolution (RVMD) at Overweight$255.00
Sep 9, 2026Stifel NicolausRevolution Medicines price target raised to $230 from $215 at Stifel$230.00
Aug 31, 2026NeedhamRevolution Medicines price target raised to $275 from $240 at Needham$275.00
Aug 28, 2026GuggenheimRevolution Medicines price target raised to $275 from $240 at Guggenheim$275.00
Aug 28, 2026UBSRevolution Medicines price target raised to $265 from $220 at UBS$265.00
Aug 27, 2026H.C. WainwrightRevolution Medicines price target raised to $280 from $195 at H.C. Wainwright$280.00
Aug 27, 2026Evercore ISIRevolution Medicines price target raised to $320 from $230 at Evercore ISI$320.00
Aug 27, 2026Raymond JamesRevolution Medicines price target raised to $248 from $230 at Raymond James$248.00
Aug 27, 2026RBC CapitalRevolution Medicines price target raised to $251 from $203 at RBC Capital$251.00

Updated 2026-11-02 17:52 UTC